Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection Obtains Drug Registration Certificate in Tajikistan.

Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company has recently received notification that their drug Enoxaparin Sodium Injection has obtained a drug registration certificate issued by the Tajikistan drug regulatory authority. Enoxaparin Sodium Injection is used to prevent venous thromboembolic diseases (prevention of intravenous blood clot formation), especially related to orthopedic or general surgery; treat established deep vein thrombosis, with or without pulmonary embolism, with mild clinical symptoms, excluding cases requiring surgical treatment or thrombolytic therapy for pulmonary embolism; used in combination with aspirin to treat unstable angina and non-Q wave myocardial infarction; and used in extracorporeal circulation during hemodialysis to prevent blood clotting.